4 Biotech Companies That Are Changing The World

iStock_000008175848_Small.jpg

 

Biogen Idec

biogen_logo.svg

 

Dementia is a menacing specter that steals the memories away from those afflicted by  it, and loved ones away from those around the patients- and until recently, there was little hope of treatment and escape. Cambridge, Massachusetts-based Biogen Idec is a leader in the development of pharmaceuticals treating forms of dementia like Alzheimer’s disease. Small-scale clinical trials conducted in March yielded very promising results, showing that the drug clearly slowed the cognitive and mental decline caused by dementia. The drug is called aducanumab, and it fights to get rid of amyloid plaque in the brain; which is widely considered to be a leading cause of many types of dementia. While it is still in the early stages of development and testing, and consequently has to be perfected before it is actually released; Biogen Idec’s new medication provides a lot of reason for optimism in the fight against dementia. 

AMGen

amgen-logo.png

AMGen is a biopharmaceutical company hailing from California’s Silicon Valley. Like many other groups in their industry, AMGen focuses much of their effort on discovering a treatment and/or cure for a particular type of disease/family of diseases- in this case, it is that cancer falls into the crosshairs of AMGen’s team of scientists and physicians. One of the most common and effective methods of treatment for cancer in the present is chemotherapy; a grueling process that can often eradicate cancerous cells, but with the nasty side effect of draining much of the strength and energy from the patient. It also weakens the immune system, leaving the body much more susceptible to viruses and infections, which is recurring problem for cancer patients. AMGen is one of the most influential and respected developers of medications that block viruses and infections. Perhaps the most well-known of these drugs is Neupogen, which helps the immune system produce white blood cells. Additionally; AMGen is the creator of another product called Vectibix- a pharmaceutical that remedies colorectal cancer. Recent tests from the early phases of the research and development process have produced astounding results.

 

Need An Industrial Mixer For The Biotech Industry?

Gilead Sciences

Gilead_Sciences_Logo.svg.png

Afflictions like HIV and hepatitis C {HCV} are amongst the most widespread and problematic diseases of the 21st century, eliminated massive swaths of people each year. Unfortunately, most medications have not been consistently effective, and many of those suffering from these diseases are unable to receive treatment whatsoever. But Gilead Sciences is doing their best to see that this changes quickly. They designed two medications called Harvoni and Solvadi, which target genotype 1 of HCV- the most common form of the virus. It is a low-maintenance pill taken once a day, and experts indicate that efficiency rates are typically over 90%. Meanwhile, another Gilead product called Truvada has been extremely impressive in fighting HIV. It has been available  on the market to patients with HiV since 2004, and was opened to at-risk individuals as preventative medicine in 2012. Recent figures indicate that Truvada is 92% effective in preventing an individual from succumbing to HIV, with one study generating 100% efficiency in their test participants. It is also amongst the powerful medications for those who have already been diagnosed with HIV and are seeking treatment for the disease.

 

Regeneron Pharmaceuticals

Regeneron-Pharmaceuticals-Inc-logo.jpg

Regeneron develops, manufactures, and distributes pharmaceutical products that treat rare but aggressive health issues like macular degeneration (an optical disease that causes complete and permanent loss of vision). There is currently no cure for macular degeneration; however, Regeneron’s product called Eylea (released in 2011) is widely considered to be the best available form of treatment. Eylea is actually injected into the patient’s eye(s) with a syringe, and the medication is usually administered on a monthly basis for the first three months, after which it typically is reduced to one treatment every other month. It has been estimated that the face value of each dosage is in the neighborhood of $1,850-$2,000 dollars; and while that might look like a rather high price, it is important to consider that Eylea can actually be more cost-effective than other treatments that require a greater number of visits to their doctors. Also, insurance brings the cost down to the range of $250-$300; making it much more affordable.

Contact Us

Sources

http://ehealthreporter.com/en/noticia/legacy-2418/

http://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html?ref=topics&_r=0

http://www.fiercebiotech.com/press-releases/vectibix-significantly-improved-progression-free-survival-second-line-treatment-kras-

http://www.fool.com/investing/general/2015/12/07/the-3-most-important-drugs-in-gilead-sciences-pipe.aspx

http://www.bloomberg.com/news/articles/2015-02-18/gilead-s-pill-can-stop-hiv-so-why-does-almost-nobody-take-it-

https://www.washingtonpost.com/news/to-your-health/wp/2015/09/04/in-new-study-hiv-prevention-pill-truvada-is-startlingly-100-percent-effective/

http://www.forbes.com/companies/regeneron-pharmaceuticals/

http://www.cbsnews.com/news/fda-approves-regeneron-drug-for-macular-degeneration/












 

tagged with biotechnology